[Biomarkers: "Found in translation"].
Despite continued increase in global Pharma R & D expenditure, the number of innovative drugs obtaining market approval has declined since 1994. The pharmaceutical industry is now entering a crucial juncture where increasing rates of attrition in clinical drug development as well as increasing development timelines are impacted by external factors such as intense regulatory pricing and safety pressures, increasing sales erosion due to generics, as well as exponential increases in the costs of bringing a drug to market. Despite these difficulties, numerous opportunities exist such as multiple unmet medical needs, the increasing incidence of certain diseases such as Alzheimer's disease, cancer, diabetes and obesity due to demographic changes, as well as the emergence of evolving markets such as China, India, and Eastern Europe. Consequently, Pharma is now responding to this challenge by improving both the productivity and the innovation in its drug discovery and development pipelines. In this regard, the advent of new technologies and expertise such as genomics, proteomics, structural biology, and molecular informatics in an integrated systems biology approach also provides a powerful opportunity for Pharma to address some of these difficulties. The key features behind this new strategy imply a discovery process based on an improved understanding of the molecular mechanism of diseases and drugs, translational research that places the patient at the center of the research process, and the application of biomarkers throughout the discovery and development phases. Moreover, new paradigms are required to improve target validation and develop more predictive cellular and animal models of human pathologies, a greater capacity in informatics-based analysis, and, consequently, a greater access to the vast sources of accumulating biological data and its integrated analysis. In the present review, we will address some of these issues and in particular emphasize how the application of biomarkers could potentially lead to improved productivity, quality, and innovation in drug discovery and ultimately better and safer medicines with improved therapeutic efficacy in specific pathologies for targeted patients.
Lockhart
Brian P
BP
Directeur de Division, Pharmacologie et Physiopathologie Moléculaires, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France. brian.lockhart@fr.netgrs.com
Walther
Bernard
B
D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D017277:Drug Approval / Q000191:economics; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods; D015507:Drugs, Investigational / Q000191:economics / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D011379:Prognosis
D015415:Biomarkers; D015507:Drugs, Investigational